Advertisement

You will be redirected to the page you want to view in  seconds.

THOUSAND OAKS, Calif. (AP) - Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test.

The results, released late Tuesday, show there's promise for similar vaccines other companies are developing.

The experimental injected drug made tumors shrink for six months in 16% of study participants. That compares with tumor shrinkage in just 2% of patients in a control group that received a standard treatment.

Amgen also says its interim analysis indicates the drug, dubbed T-VEC for short, may help patients survive longer. More definitive data are expected soon.

Shares of Thousand Oaks, Calif.-based Amgen rose $1.92, or 2.1%, to $94.32 in early afternoon trading.



Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Read the original story: Virus vaccine shrinks melanoma tumors

More In

test

Real Deals

Flip, shop and save on specials from your favorite retailers in central Ohio.

GET DEALS | COUPONS

Things To Do

MON
1
TUE
2
WED
3
THU
4
FRI
5
SAT
6
SUN
7

CLASSIFIEDS

Classifieds from across Central Ohio
Lancaster
Chillicothe
Newark
Marion
Bucyrus
Mansfield
Zanesville
Coshocton

Weeklies & Shoppers

10TV Headlines

Dispatch Headlines

METROMIX